This activity focuses on best practices in the treatment and management of patients with HER2+ breast cancer. Topics include: current treatment principles for HER2+ breast cancer, incorporating recently presented pivotal trial data for new treatment options, the emerging role of biosimilars and the implications for practice. The discussion is multidisciplinary and touches upon surgical consideration, pathology, radiation and systemic therapy, as well as the coordination of care.
1.75 AMA PRA Category 1 Credits™
1.75 Contact Hours
Jul 31, 2017
Aug 1, 2018
Kimberly Blackwell, MDDuke University School of Medicine
Durham, North Carolina, United States
David M. Euhus, MDJohns Hopkins Medical Institute
Baltimore, Maryland, United States
Joyce O’Shaughnessy, MDBaylor University Medical Center
Dallas, Texas, United States
Julia White, MDThe Ohio State University
Comprehensive Cancer Center
Columbus, Ohio, United States
- Microinvasive or Small, Node-Negative Disease
- Surgical Considerations for HER2+/Node+ Disease After pCR
- Radiation Considerations for HER2+/Node+ Disease After pCR
- Metastatic HER2+ Breast Cancer
- Risk Reduction with Extended Adjuvant HER2-Targeted Treatment
- Biosimilars: Anticipated Challenges and Opportunities
- Interactive Q&A With the Audience
- Interactive Case Discussions
- Conclusions and prIME Points™
This educational activity is specifically designed for medical oncologists, internists, nurses, pharmacists, and other healthcare providers who treat/manage patients with breast cancer.
After successful completion of this educational activity, participants should be able to:
- Recognize equivocal results for HER2 testing
- Utilize guidelines to collaborate with the pathologist to obtain appropriate follow-up testing
- Select optimal therapy based upon patient and disease characteristics
- Review the guidelines for immunohistochemical testing in patients with breast cancer
- Counsel patients on the role of testing in breast cancer and the rationale for targeted therapies
- Evaluate guideline-based treatment options utilizing patient and disease factors
This educational activity is supported by a grant from Genentech.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education activity was approved by the ONS, an accredited approver by the American Nurses Credentialing Center’s COA.
A maximum of 1.75 contact hours may be earned for successful completion of this program. The criteria for successful completion include attending the full program and completing the evaluation.
Content in this learning activity is applicable to meeting individual requirements for certification renewal through the Oncology Nursing Certification Corporation’s Independent Learning Needs Assessment (ILNA) renewal method. Visit www.oncc.org for complete details on oncology nursing certification.
This activity is provided by prIME Oncology.
Method of Participation
A link to the posttest is available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 80% or higher.
Disclosure of Relevant Financial Relationships
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Dr Blackwell has disclosed that she has received consulting fees from Celgene, Coherus, Eli Lilly, Genentech, GI Therapeutics, Novartis, Pfizer, Puma, and Sandoz. She has also received support for travel to meetings from Celgene, Coherus, Eisai, Puma, Genentech, Macrogenics, Merck, Novartis, Pfizer, and Sandoz. She has received research funding for her institution from Celgene, Genentech, Novartis, and Pfizer. She has also received fees for her participation in advisory or review activities from Advaxis, Bayer, Eisai, Macrogenics, Merck, Novartis, Pfizer, and Pierian Biosciences. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Euhus has nothing to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr O’Shaughnessy discloses participation in advisory boards and consultant work for AbbVie, Arno Therapeutics, AstraZeneca, Celgene Corporation, Concept Therapeutics, Eisai, Nektar Therapeutics, Genentech, Lilly, Novartis Pharmaceuticals, Pfizer, Sandoz, and Zymeworks. She has also received support for travel to meetings from AbbVie, Celgene Corporation, Nektar Therapeutics, Lilly, Novartis Pharmaceuticals, Pfizer, Sandoz, and Zymeworks. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr White has nothing to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
The employees of prIME Oncology have disclosed:
- Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
- Zach Hartman, PhD (scientific content reviewer/planner) – Stock or stock options in Advaxis Inc and Ariad Pharmaceuticals
- Tristin Abair, PhD (medical writer) – no relevant financial relationships
- Brooke Balun, MSN, APRN-BC, AOCNP (Lead Nurse Planner) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.